E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Treatment of excessive sleepiness in adult patients with narcolepsy |
|
E.1.1.1 | Medical condition in easily understood language |
Treatment of excessive sleepiness in adult patients with narcolepsy; to increase the ability to stay awake throughout the day. |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Nervous System Diseases [C10] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 19.0 |
E.1.2 | Level | HLT |
E.1.2 | Classification code | 10028716 |
E.1.2 | Term | Narcolepsy and associated conditions |
E.1.2 | System Organ Class | 100000004873 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To evaluate the efficacy of JZP-110 administered once daily for up to 12 weeks in doses of 75, 150, and 300 mg compared to placebo in the treatment of excessive sleepiness in adult subjects with narcolepsy. |
|
E.2.2 | Secondary objectives of the trial |
To evaluate the safety and tolerability of JZP-110 administered once daily for up to 12 weeks in doses of 75, 150, and 300 mg compared to placebo in the treatment of excessive sleepiness in adult subjects with narcolepsy. To characterize the pharmacokinetics (PK) of JZP-110 in subjects with narcolepsy using sparse sampling methods. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Each subject must meet the following criteria to be enrolled in the study:
1.Males and females between 18 and 75 years of age, inclusive. 2. Diagnosis of narcolepsy according to ICSD-3 or DSM-5 criteria. 3. Baseline mean sleep latency ≤25 minutes as documented by the mean of the first four trials of the Baseline 5-trial MWT. 4. Baseline Epworth Sleepiness Scale (ESS) score ≥10. 5. Usual nightly total sleep time of at least 6 hours. 6. Body mass index from 18 to <45 kg/m2. 7. Consent to use a medically acceptable method of contraception for at least 2 months prior to the first dose of study drug, throughout the entire study period, and for 30 days after the study is completed. 8. Willing and able to comply with the study design schedule and other requirements. 9. Willing and able to provide written informed consent. |
|
E.4 | Principal exclusion criteria |
1. Female subjects who are pregnant, nursing, or lactating. 2. Usual bedtime later than 1 AM (0100 hours). 3. Occupation requiring nighttime or variable shift work. 4. Moderate or severe obstructive sleep apnea (OSA) on the baseline PSG. 5. Any other clinically relevant medical, behavioral, or psychiatric disorder other than narcolepsy that is associated with excessive sleepiness. 6. History or presence of bipolar disorder, bipolar related disorders, schizophrenia, schizophrenia spectrum disorders, or other psychotic disorders according toDSM-5 criteria. 7. History or presence of any acutely unstable medical condition, behavioral or psychiatric disorder (including active suicidal ideation), or surgical history that could affect the safety of the subject or interfere with study efficacy, safety, PK assessments, or the ability of the subject to complete the trial per the judgment of the Investigator. 8. History of bariatric surgery within the past year or a history of any gastric bypass prcedure. 9. Presence of renal impairment or calculated creatinine clearance <60 mL/min. 10. Clinically significant ECG abnormality, in the opinion of the Investigator. 11. This criteria has been removed. 12. Presence of significant cardiovascular disease including but not limited to: myocardial infarction within the past year, unstable angina pectoris, symptomatic congestive heart failure (ACC / AHA stage C or D), revascularization procedures within the past year, ventricular cardiac arrhythmias requiring automatic implantable cardioverter defibrillatory (AICD) or medication therapy, uncontrolled hypertension, systolic blood pressure ≥155 mmHg or diastolic blood pressure ≥95 mmHg (at screening, or consistently across Baseline measures according to protocol specifications), or any history of cardiovascular disease or any significant cardiovascular condition that in the investigator's opinion may jeopardize subject safety in the study. 13. Laboratory value(s) outside the laboratory reference range that are considered to be clinically significant by the Investigator (clinical chemistry, hematology, and urinalysis); NOTE: Screening labs may be repeated once. 14. Excessive caffeine use one week prior to Baseline assessments or anticipated excessive use during the study defined as >600 mg/day of caffeine. 15. Use of any over-the-counter (OTC) or prescription medications that could affect the evaluation of excessive sleepiness within 7 days prior to the Baseline visit, or planned use of such drug(s) at some point throughout the duration of the study. Examples of excluded medications include OTC sleep aids orstimulants (e.g., pseudoephedrine), methylphenidate, amphetamines, modafinil, armodafinil, sodium oxybate, pemoline, trazodone, hypnotics, benzodiazepines, barbiturates, and opioids. Medications should be discontinued such that the subject has returned to his/her baseline level of daytime sleepiness at least 7 days prior to the Baseline visit, in the opinion of the Investigator. 16. Use of any medications that could affect the evaluation of cataplexy within 7 days prior to the Baseline visit, or planned use of such drug(s) at some point throughout the duration of the study. Examples of excluded anti-cataplectic medications include selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), monoamine oxidase inhibitors (MAOIs), anti-convulsant agents, and sodium oxybate. These drugs will be discontinued if they are taken for the treatment of narcolepsy and discontinuation is deemed safe by the Investigator. Sodium oxybate should be sufficiently washed out such that the subject has returned to his/her baseline level of cataplexy at least 7 days prior to the Baseline visit, in the opinion of the Investigator. 17. Received an investigational drug in the past 30 days or five half-lives (whichever is longer) prior to the Baseline visit, or plans to use an investigational drug (other than the study drug) during the study. 18. Previous exposure to or participation in a previous clinical trial of JZP-110 (ADX-N05, R228060, YKP-10A). 19. Current or past (within the past 2 years) diagnosis of a moderate or severe substance use disorder according to DSM-5 criteria. 20. Nicotine dependence that has an effect on sleep (e.g., a subject who routinely awakens at night to smoke). 21. Current, past (within the past 2 years), or seeking treatment for a substance related disorder. 22. Urine drug screen positive for an illicit drug of abuse (including cannabinoids) at screening or at any point throughout the duration of the study, except for a prescribed drug (e.g., amphetamine) at screening. 23. History of phenylketonuria (PKU) or history of hypersensitivity to phenylalanine-derived products. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Efficacy Endpoints
Co-primary Efficacy Endpoint:
• MWT: Change in the mean sleep latency time (in minutes) as determined from the first four trials of a 40-minute MWT from Baseline to Week 12
• ESS: Change in ESS score from Baseline to Week 12
|
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
During the Treatment Phase, subjects will return to the investigative site to complete efficacy and safety assessments at the end of Weeks 1, 4, 8, and 12 |
|
E.5.2 | Secondary end point(s) |
Key Secondary Efficacy Endpoint:
• PGIc: Percentage of subjects reported as improved (minimally, much, or very much) on the PGIc at Week 12
Other Secondary Endpoints:
• Time course of efficacy on the MWT: Change in sleep latency time (in minutes) on each of the 5 MWT trials • CGIc: Percentage of subjects reported as improved (minimally, much, or very much) at Week 12 • MWT: Change in the mean sleep latency time (in minutes) as determined from the first four trials of a 40-minute MWT from Baseline to Week 1 and Week 4 • ESS: Change in ESS score from Baseline to Week 1, Week 4, and Week 8 • PGIc: Percentage of subjects reported as improved at Week 1, Week 4, and Week 8 • CGIc: Percentage of subjects reported as improved at Week 1, Week 4, and Week 8
Functional Outcomes and Quality of Life Endpoints • FOSQ-10: Change in the total score from Baseline to Week 1, Week 4, Week 8, and Week 12 • SF-36v2: Change in the total score and change in the 8 subscales from Baseline to Week 4, Week 8, and Week 12 o EQ-5D-5L: EQ-5D Dimensions: • Number and percentage of subjects in each of the 5 levels (e.g., no problem, slight problem, moderate problem, severe problem, unable) for each dimension (e.g., mobility, self-care) over time • Number and percentage of subjects reporting any problems (levels 2-5) for each dimension (e.g., mobility, self-care) over time o EQ VAS: Mean and SD or median with 25th and 75th percentiles for the VAS at Baseline, Week 1, Week 4, Week 8 and Week 12. Change in the mean VAS scores from Baseline to Week 1, Week 4, Week 8, and Week 12 o EQ-5D-5L Index: Index value at Baseline to Week 1, Week 4, Week 8, and Week 12 • WPAI:SHP: Percent work time missed due to problem over time, percent impairment while working due to problem over time, percent overall work impairment due to problem over time, and percent activity impairment due to problem over time
Exploratory Endpoints • Number of Cataplexy Attacks: Change in the mean weekly number of cataplexy attacks in the subset of subjects who report the presence of cataplexy at randomization from Baseline to Week 1, Week 4, Week 8, and Week 12 • Change in PSG parameters including total sleep time (TST), Stages N1, N2, N3, wake after sleep onset (WASO), number of awakenings, AI, AHI, number of central apneas, SaO2 nadir, and SaO2 mean from Baseline to Week 1, Week 4, and Week 12.
Safety Endpoints To evaluate the safety and tolerability evaluations as determined by the occurrence of and/or changes in: • Treatment-emergent adverse events • Change in clinical laboratory tests (chemistry, hematology, and urinalysis) • Vital signs • 24 hour ambulatory blood pressure monitoring • 12-lead electrocardiograms (ECGs) • Physical examination • C-SSRS |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
During the Treatment Phase, subjects will return to the investigative site to complete efficacy and safety assessments at the end of Weeks 1, 4, 8, and 12 |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | Yes |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 4 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 1 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 15 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Canada |
Finland |
France |
Germany |
Netherlands |
United States |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 4 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 1 |
E.8.9.2 | In all countries concerned by the trial months | 8 |
E.8.9.2 | In all countries concerned by the trial days | 0 |